# Modafinil's Effects on Cognition in Remitted MDD

> **NCT03620253** · PHASE3 · TERMINATED · sponsor: **Unity Health Toronto** · enrollment: 9 (actual)

## Conditions studied

- Major Depressive Disorder
- Cognitive Impairment

## Interventions

- **DRUG:** Modafinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03620253
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-15
- **Primary completion:** 2019-08-06
- **Final completion:** 2019-08-06
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Principal Investigator left study site
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620253, "Modafinil's Effects on Cognition in Remitted MDD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03620253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*